Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
2921-2940 of 3,900 trials

Solid Tumors: MK-0472 Study

We are investigating the effects of MK-0472 in people with solid tumors. This study aims to understand how well this treatment works compared to standard options.

Solid Tumors>2 yearsSafety phase (I)Oncology

Myelodysplastic Syndromes: Elritercept Treatment Study

We are testing elritercept to see if it can help reduce the need for blood transfusions in adults with certain types of myelodysplastic syndromes. The study will also look at how safe and tolerable the treatment is.

Myelodysplastic Syndrome (MDS)Anemia6-12 monthsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementHematologyInternal Medicine

HER2-Expressing Cancers: VIR-5818 and Pembrolizumab Study

We are testing a new treatment combining VIR-5818 with Pembrolizumab for patients with advanced or metastatic HER2-expressing cancers. This study aims to evaluate the safety and effects of this combination.

HER2-Positive Cancers>2 yearsSafety phase (I)Oncology

Efgartigimod for Early Treatment of Generalized Myasthenia Gravis

We are studying whether efgartigimod can improve daily activities and quality of life for patients with generalized myasthenia gravis and specific antibodies. This trial will help us understand its effectiveness and tolerability as an early treatment option.

Generalized Myasthenia Gravis6-12 monthsMonitoring phase (IV)11-15 visitsNo PlaceboStandard MedicinesPartially RemoteNeurology

RR001 Gene Therapy for Locally Advanced Pancreatic Cancer

We are studying a new gene therapy combined with chemotherapy to see if it is safe and effective for patients with locally advanced pancreatic cancer. The trial will help determine the best dose and how well this treatment works.

Pancreatic CancerLocally Advanced Pancreatic Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncology

Graves' Disease: IMVT-1402 Treatment Study

We are studying a new treatment called IMVT-1402 for adults with Graves' disease. The aim is to see if it can improve thyroid hormone levels compared to a placebo.

Grave's Disease1-2 yearsEfficacy phase (II)Investigational MedicinesEndocrinology

Huntington's Disease: Innovative Biomarker Study

We are exploring new imaging and cognitive markers to better understand how Huntington's disease progresses. This study aims to identify effective ways to track the disease from early stages.

Huntington's DiseaseConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementNeurologyPsychiatry

Advanced Solid Tumors: Eftilagimod Alpha Treatment

We are exploring a new treatment using eftilagimod alpha for patients with advanced solid tumors. The study looks at its safety and how it works with other therapies.

Non-Small Cell Lung Cancer (NSCLC)Urothelial CarcinomaMalignant Solid Tumor>2 yearsSafety phase (I)Oncology

Multiple Myeloma: Belantamab Mafodotin vs. Daratumumab

We are studying a new treatment combination for people with newly diagnosed multiple myeloma who cannot have stem cell transplants. The goal is to see if it works better and is safer than the current standard treatment.

Multiple MyelomaConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyOncology

Chronic Kidney Disease: Dapagliflozin and Balcinrenone Study

We are investigating how dapagliflozin, alone or with balcinrenone, affects kidney function and fluid balance in people over 50 with chronic kidney disease. This study aims to understand the potential benefits of these treatments on energy metabolism and urine concentration.

Stage 3 Chronic Kidney Disease1-2 yearsEfficacy phase (II)Investigational MedicinesEndocrinologyNephrology

Ifinatamab Deruxtecan for Metastatic Prostate Cancer

We are studying ifinatamab deruxtecan to see if it is safe and effective for men with metastatic castration-resistant prostate cancer. This trial will help us understand how well it works compared to other treatments.

Metastatic Castrate Resistant Prostate Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Migraine Aura: Amiloride Study

We are investigating whether amiloride can help prevent migraine aura and headaches in people who experience these symptoms. The study will also assess the safety of this medication.

Migraine Aura6-12 monthsEfficacy phase (II)Confirmation phase (III)Standard MedicinesInternal MedicineNeurology

Chronic Myeloid Leukemia: Asciminib Treatment Study

We are studying Asciminib for patients with Chronic Myeloid Leukemia who have the T315I mutation and have not responded to ponatinib. The trial aims to see how well it works and how safe it is.

Chronic Myeloid Leukemia>2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteOncology

Hydroxychloroquine for Early Systemic Sclerosis

We are studying whether adding hydroxychloroquine to standard treatments helps improve symptoms in people with early systemic sclerosis. The trial will assess its safety and effectiveness compared to a placebo.

Systemic Sclerosis1-2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesInternal MedicineRheumatology

Kamada-AAT for Inhalation in Alpha-1 Antitrypsin Deficiency

We are studying a new inhalation treatment for adults with congenital Alpha-1 Antitrypsin Deficiency to see if it improves lung function compared to a placebo. The trial also looks at safety and immune responses to the treatment.

Congenital Alpha-1 Antitrypsin Deficiency>2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementInternal MedicinePulmonology

Serotonin and Decision-Making: A Behavioral Study

We are investigating how serotonin influences learning and decision-making in individuals. The study also looks at how personal traits like perfectionism and impulsivity relate to these behaviors.

Healthy Participants≤3 monthsMonitoring phase (IV)≤5 visitsStandard MedicinesPsychiatry

Severe Influenza: Early Oseltamivir Carboxylate Levels

We are studying how low levels of oseltamivir carboxylate in critically ill patients with severe influenza affect their recovery and survival. This research may help improve treatment for patients in intensive care.

Severe Influenza Infection>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesInfectious DiseasesInternal Medicine

Retinitis Pigmentosa: GS030 Gene Therapy Study

We are evaluating a new gene therapy to see if it is safe and can improve vision in people with retinitis pigmentosa. Participants will receive a single injection and undergo light stimulation to assess potential benefits.

Retinitis Pigmentosa1-2 yearsSafety phase (I)Efficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOphthalmology

Advanced Ovarian Cancer: Niraparib Alone vs. Niraparib with Bevacizumab

We are studying whether combining Niraparib with Bevacizumab improves outcomes for patients receiving chemotherapy for advanced ovarian cancer. This trial aims to see if the combination treatment helps patients live longer without their cancer progressing.

Ovarian CancerPeritoneal CarcinomaFallopian Tube CancerConfirmation phase (III)16-20 visitsNo PlaceboStandard MedicinesOncology

Seizure Treatment After Cardiac Arrest: TELSTAR-2 Trial

We are studying whether a stepwise anti-seizure treatment helps improve outcomes for comatose patients who have seizures after cardiac arrest. This trial also looks at the healthcare costs associated with this treatment.

Cardiac ArrestComatoseStatus EpilepticusConfirmation phase (III)No PlaceboStandard MedicinesCardiologyInternal MedicineNeurology